{"id":"tp-40147","type":"article-newspaper","title":"Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40147","datePublished":"2026-10-24T16:51:32.000Z","dateModified":"2026-10-24T16:51:32.000Z","language":"en","abstract":"Patients with PIK3CA-mutated disease and no liver metastases had median progression-free survival of 21.5 months on the gedatolisib triplet, versus 9.1 months on the control regimen.","section":"Business","references":[]}